Hormone replacement therapy and hemostasis: Effects in Brazilian postmenopausal women

Maturitas

Volumn 52, Issue 3-4, 2005, Pages 249-255

  Callejon, Daniel R ^a   Franceschini, Silvio A ^b   A Montes, Marlise B ^a   T Toloi, Maria R ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

Author keywords

Hemostasis; Hormone replacement therapy; Postmenopausal women

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 7; ESTRADIOL; FIBRIN DEGRADATION PRODUCT; FIBRINOGEN; MEDROXYPROGESTERONE ACETATE; PLASMINOGEN; PROTEIN C; PROTEIN S; PROTHROMBIN; THROMBIN;

ADULT; ARTICLE; BLOOD CLOTTING; BRAZIL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DOSAGE FORM; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; LONGITUDINAL STUDY; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; POSTMENOPAUSE; PROSPECTIVE STUDY; PROTHROMBIN TIME;

ADMINISTRATION, ORAL; ADULT; BLOOD COAGULATION FACTORS; BRAZIL; CONTRACEPTIVE AGENTS, FEMALE; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HEMOSTASIS; HORMONE REPLACEMENT THERAPY; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; POSTMENOPAUSE; PROSPECTIVE STUDIES; PROTHROMBIN TIME; TREATMENT OUTCOME;

EID: 27644434459     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2005.02.024     Document Type: Article

References (39)

1. F. Al-Azzawi The menopause and its treatment in perspective Postgrad Med J 77 2001 292 304
2. B. Ettinger Prevention of osteoporosis: treatment of estradiol deficiency Obstet Gynecol 72 1988 12S 17S
3. G.A. Coldtiz, W.C. Willett, and M.J. Stamfer Menopause and the risk of coronary heart disease in women N Engl J Med 316 1987 1105 1110
4. G.F. Gensini, S. Micheli, D. Prisco, and R. Abbate Menopause and risk cardiovascular disease Thromb Res 84 1996 1 19
5. T.W. Meade, A.P. Haines, J.D. Imeson, Y. Stirling, and S.G. Thompson Menopausal status and haemostatic variables Lancet i 1983 22 24
6. A.J. Lee, G.D.O. Lowe, W.C.S. Smith, and H. Tunstall-Peda Plasma fibrinogen in women: relationship with oral contraception, the menopause and HRT Br J Haematol 83 1993 616 621
7. O.C.E. Gebara, M.A. Mittleman, and P. Sutherland Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study Circulation 91 1995 1952 1958
8. V.M. Barnabei, D. Grady, and D.W. Stovall Menopausal symptoms in older women and the effects of treatment with hormone therapy Obstet Gynecol 100 2002 1209 1218
9. D. Grady, S.M. Rubin, and D.B. Petitti Hormone therapy to prevent disease and prolong life in postmenopausal women Ann Intern Med 117 1992 1016 1037
10. M.J. Stampfer, W.C. Willett, G.A. Coldtiz, B. Rosner, F.E. Speizer, and C.H. Hennekens A prospective study of postmenopausal estrogen therapy and coronary heart disease N Engl J Med 313 1985 1044 1049
11. J.C. Stevenson Cardiovascular effects of oestrogens J Steroid Biochem Mol Biol 74 2000 387 403
12. A.A. Nalbusi, A.R. Folsom, A. White, W. Patsch, G. Heiss, and K.K. Wu Association of hormone replacement therapy with various cardiovascular risk factors in postmenopausal women N Engl J Med 328 1993 1069 1075
13. O. Gökmen, and E.G.Y. Eyi Hormone replacement therapy and lipid-lipoprotein concentrations Eur J Obstet Gynecol Reprod Biol 85 1999 31 41
14. S. Hurley, D. Grady, and T. Bush Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women JAMA 280 1998 605 613
15. Writing Group for the Women's Health Initiative Investigators Risk and benefits of estrogen plus progestin in healthy postmenopausal women JAMA 288 2002 366 368
16. V. Beral, E. Banks, and G. Reeves Evidence from randomised trials on the long-term effects of hormone replacement therapy Lancet 360 2002 942 944
17. J. Miller, B.K. Chan, and H.D. Nelson Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force Ann Intern Med 136 2002 680 690
18. U.H. Winkler Hormone replacement therapy and hemostasis: principles of a complex interaction Maturitas 24 1996 131 145
19. Y.G. Caine, K.A. Bauer, and S. Barzegar Coagulation activation following estrogen administration to postmenopausal women Thromb Haemost 68 1992 392 395
20. U.B. Kroon, G. Silfverstolpe, and L. Tengborn The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables Thromb Haemost 71 1994 420 503
21. B. Walsh, L. Kuller, and R. Wild Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women JAMA 279 1998 1445 1451
22. J. Gilabert, A. Estelles, and A. Cano The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status Am J Obstet Gynecol 173 1995 1849 1854
23. D. Croock The metabolic consequences of treating postmenopausal women with non-oral hormone replacement therapy Br J Obstet Gynecol 104 1997 4 13
24. P.Y. Scarabin, E. Oger, and G. Plu-Bureau Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk Lancet 362 2003 428 432
25. T. McCarthy, V. Dramusic, and S. Ratnam Use of two types of estradiol-releasing skin patches for menopausal patients in a tropical climate Am J Obstet Gynecol 166 1992 2005 2010
26. S.T.F. Alves, M.A.S. Gomes, and R. Clapauch Comparison of gel and patch estradiol replacement in Brazil, a tropical country Maturitas 36 2000 69 74
27. H. Jick, L.E. Derby, M.W. Myers, C. Vasilakis, and K.M. Newton Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens Lancet 348 1996 981 983
28. E. Daly, M.P. Vessey, M.M. Hawkins, J.L. Carson, P. Gough, and S. Marsh Risk of venous thromboembolism in users of hormone replacement therapy Lancet 348 1996 977 980
29. H.J. Teede, B.P. McGranth, and J.J. Smolich Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis Arterioscler Thromb Vasc Biol 20 2000 1404 1409
30. W.M. Van Baal, J.J. Emeis, M.J. van der Mooren, H. Kessel, P. Kenemans, and CD.A. Stehouwer Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomized, placebo- controlled 12-week study Thromb Haemost 83 2000 29 34
31. K.K. Koh, K.M.c.D. Horne III, G. Csako, M.A. Waclawiw, and R.O. Cannon III Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women Am J Cardiol 83 1999 466 469
32. K.K. Koh, R. Mincemoyer, and M.N. Bui Effects of hormone replacement therapy on fibrinolysis in postmenopausal women N Engl J Med 336 1997 683 690
33. M.S. Post, M.J. Van der Mooren, and W.M. Van Baal Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: A randomized placebo-controlled study Am J Obstet Gynecol 189 2003 1221 1227
34. P.Y. Scarabin, M. Alhenc-Gelas, G. Plu-Bureau, P. Taisne, R. Agher, and M. Aiach Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial Arterioscler Thromb Vasc Biol 17 1997 3071 3078
35. The Writing Group for the Estradiol Clotting Factors Study Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study Thromb Haemost 75 1996 476 480
36. S. Vehkavaara, A. Silveira, and T. Hakala-ala-Pietilä Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women Thromb Haemost 85 2001 619 625
37. J.J. Sidelmann, J. Jespersen, L.F. Andersen, and S.O. Skouby Hormone replacement therapy and hypercoagulability. Results from the Prospective Danish Climacteric Study Br J Obstet Gynaecol 110 2003 541 547
38. M. Whitehead Progestin and androgens Fertil Steril 62 Suppl 2 1994 161S 167S
39. M. Levi, S. Middeldorp, and H.R. Buller oral contaceptives and hormonal replacement therapy cause an imbalance in coagulation and fibrinolysis, which may explain the increased risk of venous thromboembolism Cardiovasc Res 41 1999 21 24